Drugs / ACE2016
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06415487 | Aug 2024 → Dec 2026 expected | metastatic neoplasm | Acepodia Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACE2016 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06415487 ↗ |
| Modality | Cell therapy | “Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy” NCT06415487 ↗ |
| Target | EGFR | “anti-EGFR” NCT06415487 ↗ |